Shenyang Xingqi Pharmaceutical (300573.SZ) announced that the company's research and development of SQ-22031 eye drops recently completed the first subject enrollment in the "Evaluation of the safety, tolerance, and pharmacokinetics of SQ-22031 eye drops in healthy subjects in a single-center, randomized, double-blind, placebo-controlled phase I clinical trial" and officially entered the clinical trial.
The phase I study of SQ-22031 eye drops is a randomized, double-blind, placebo-controlled single/multiple dose administration trial to evaluate the safety of SQ-22031 eye drops in healthy subjects, and to analyze and evaluate its immunogenicity and pharmacokinetic characteristics.
